

South Carolina
Department of Health and Human Services
1801 Main Street Columbia, South Carolina 29201-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 5, 2025
MINUTES

I. Welcome and Call to order..... Edward Behling, MD
• Called to order at 4:08 pm.

Freedom of Information Act/Americans with Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

II. Roll Call Kimberly Bristow, RPh
• Committee members were encouraged to attend future meetings in person.
• Mrs. Bristow welcomed the committee and introduced two new P&T members: Dr Robert J. Collins (Oncologist) and Michelle Jackson, PharmD.

Committee Members' Present:

Edward Behling, MD	Kelly Barth, DO	Duncan Norton, MD
Heather Hembree, PharmD	Jony Bolinger, MD	Garrett Whittle, PharmD
Katherine Lewis, MD	Cheryl Hartvigsen, RPh	
Robert J. Collins, MD, MPH	Michelle Jackson, PharmD	

SC DHHS Staff:

Ashley Sirianni, DNP, FNP-BC
Kevin Wessinger, MD
Kimberly Bristow, RPh
Sarah Hearn-Bailey, Esq.
Brandie Crider, BSBA, CPhT
Tawanna Zeigler, MHSA, CPhT

PRIME:

Lori Ash
Lisa Correll, PharmD
Manisa Bulsara, PharmD

III. Approval of Minutes from August 6, 2025..... P&T Committee

- The draft minutes from the previous P&T Committee meeting August 6, 2025, were emailed to the members for review prior to the meeting.
 - Duncan Norton, MD motioned to approve the previous P&T meeting minutes and Garrett Whittle, PharmD seconded the motion for approval. The minutes were approved unanimously.

IV. State Updates Kevin Wessinger, MD and Kim Bristow, RPh

- Dr. Wessinger notified committee members that GLP-1 medications for obesity would be removed from the PDL 12/31/2025. There will be no changes to GLP-1 products with respect to the indication for diabetes. Wegovy will continue to be covered for indications other than obesity (e.g., MACE/MASH). If members are currently taking Wegovy for these indications, they may require a new Prior Authorization for those indications.
- Mrs. Bristow notified committee members effective 1/1/2026 the MCOs will be employing the Fee for Service (FFS) reimbursement methodology utilizing lesser than logic at point of sale for In-State Independent Pharmacies, this will replace the Quarterly State Directed payments for prescriptions filled after 12/31/2025.

V. Pharma Updates..... Manisa Bulsara, PharmD

- Dr. Bulsara informed the committee that the State plans to continue utilizing the randomization process for meeting requests in 2026. There will be one 40-minute meeting per entity per year. Any questions or concerns can be directed to scpharma@primetherapeutics.com.

VI. New Drugs to Market..... Manisa Bulsara, PharmD

- Sephience™ (sepiapterin)
- Brinsupri™ (brensocatib)
- Wayrilz™ (rilzabrutinib)
- Yeztugo® (lenacapavir)
- Enbumyst™ (bumetanide nasal spray)
- Forzinity™ (elamipretide)
- Inluriyo™ (imlunestrant)
- Crenessity™ (crinecerfont)
- Tryptyr™ (acoltremon)®
- Ekterly® (sebetalstat)
- Anzupgo®(delgocitinib)
- Orlynvah™ (sulopenem etzadroxil and probenecid)
- Papzimeos™(zopapogene imadenovec-drda)

- Blujepta™ (gepotidacin)
- Zurnai™ (nalmefene)

VII. Drug Classes for Review Manisa Bulsara, PharmD

- Urea Cycle Disorders- N-Acetylglutamate Synthase (NAGS) Deficiency
 - No speaker/presenter.
 - Adding Carbaglu® tablets (carglumic acid tablets) as preferred- clinical criteria will apply.
 - Jony Bolinger, MD motioned for this to be approved, and Duncan Norton, MD, seconded the motion for approval. This change was approved unanimously.
- Anti-Parkinson, Other
 - No speaker/presenter.
 - The following products were added as preferred: amantadine cap/solution, benz tropine tab, bromocriptine cap/tab, carbidopa-levodopa ODT, carbidopa-levodopa tab and ER tab, pramipexole tab, ropinirole tab, selegiline cap/tab, trihexyphenidyl elixir.
 - The following products were added as non-preferred: Apokyn® (apomorphine), Azilect® (rasagiline), carbidopa (Lodysyn®), carbidopa-levodopa-entacapone (Stalevo®), Crexant® ER, Dhivy™, Duopa® Suspension, entacapone (Comtan®), Gocovri®, Inbrija™ inhalation, Neupro® patch, Nourianz™, Ongentys®, pramipexole ER (Mirapex® ER), ropinirole ER (Requip® XL), Rytary® ER, tolcapone (Tasmar®), Xadago®. All non-preferred medications in this category will require trial and failure of 2 preferred agent with Clinical Criteria applied, with one exception- Gocovri® carries additional indications outside of Parkison's.
 - Garrett Whittle, PharmD motioned for this change to be accepted and Heather Hembree, PharmD seconded the motion for approval. This change was approved unanimously.
- Antihyperlipidemic, Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
 - Speaker: Deanna Phillips, PharmD (Amgen), who provided testimony on Repatha®.
 - Recommendation to add Repatha® (evolocumab) as Preferred, with Praluent® (alirocumab) as Non-Preferred, clinical criteria will apply for drugs within this class.
 - Dr. Behling inquired as to the number of claims on the non-preferred product (Praluent) appeared to be 3-4%, did we have the data, was this for indication/age? Dr. Bulsara noted

that information was not captured but happy to take it back for follow-up. Dr. Behling noted no follow-up needed.

- Duncan Norton, MD motioned for this to be approved, and Garrett Whittle, MD seconded the motion for approval. The recommendation was approved unanimously.

VIII. Drug Classes for Re-Review..... Manisa Bulsara, PharmD

- Anti-Convulsants, Carbamazepine Derivatives
 - No speaker/presenter.
 - Adding carbamazepine suspension to preferred.
 - Dr. Norton did inquire on non-preferred product utilization, Dr. Bulsara noted utilization was in the XR and suspension.
 - Duncan Norton, MD motioned to approve, Jony Bolinger, MD seconded the motion. This change was approved unanimously.
- NSAIDs, oral
 - No speaker/presenter.
 - Recommendation to add celecoxib cap as preferred.
 - Garrett Whittle, PharmD motioned to approve, Jony Bolinger, MD seconded the motion. This change was approved unanimously.
- Anti-Migraine, Triptan and Other
 - One speaker: Teena Abraham, MS, PharmD (Axsome) provided testimony on Symbravo.
 - Dr. Bulsara shared the naming convention of the class was revised to capture other 'non-triptan' products. The following products were recommended to be added as non-preferred: diclofenac potassium powder packet, Elyxyb™ solution and Revvow™ tab.
 - Cheryl Hartvigsen, RPh motioned the recommendation for approval, Duncan Norton, MD seconded the motion. The recommendation was approved unanimously.

IX. Housekeeping..... Manisa Bulsara, PharmD

- Pharma mailbox: scpharma@primetherapeutics.com
- The effective dates for the medications in the classes presented during this meeting will be 4/1/2026.
- Dr Bulsara also provided the committee with Journavx data 7/1/2025- 10/15/2025, this was a prior request from the committee. There were 90 claims with approximately 80 patients. Given there is still interest in the claims data, Dr. Behling requested that an additional set of data be shared at the next meeting.

Dr. Behling asked for a motion to adjourn: Duncan Norton, MD motioned, Garrett Whittle, PharmD seconded the motion.

X. Next P&T Meeting will be held on Wednesday, February 4, 2026, at 4pm.

- All P&T Committee members are encouraged to attend in person.

XI. Adjournment

- Meeting adjourned at 4:57 p.m.